Global Pharma Reach Cisiv’s Baseline Plus platform is already used by 90% of the top global pharmaceutical companies and supports 200+ projects, indicating strong market validation and an established target audience of large pharma and biotech organizations for expansion or deeper engagement.

End-to-End Real-World Data The platform covers EDC, eConsent, ePRO, eCOA, eDiary, Surveys, Safety, and e-Source across site-based, decentralized, and hybrid studies, presenting opportunities to upsell modules, integrations, or consulting services to broaden data capture and trial efficiency.

Cost Reduction Benefit Cisiv claims a 60% reduction in data management costs, a compelling value proposition for cost-conscious sponsors seeking efficiency gains, especially in late-stage trials where data volume and complexity are high.

Strategic Partnerships Past collaborations with Clinerion and Claret Capital Partners suggest a receptive ecosystem for alliance-based growth, presenting avenues to pursue joint offerings, co-marketing, or investment-backed expansion in global markets.

Financial Opportunity With reported revenue between 1M and 10M and a niche yet scalable platform, Cisiv may be poised for accelerated growth through enterprise deals, regional expansions (London base supports UK/EU access), and targeting mid-to-large pharma clients seeking real-world evidence capabilities.